Zhejiang Shengda Pharm (603079) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Zhejiang Shengda Pharm stock ¥5.77, price ¥11.33, that is 49.1% below the price, quality 46 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range ¥7.62 – ¥21.99 · fair‑value band ¥4.25 – ¥5.98 · the ¥11.33 price screens above the ¥5.77 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Zhejiang Shengda Pharm in your weekly email
Every Wednesday you see whether Zhejiang Shengda Pharm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Zhejiang Shengda Bio-Pharm Co., Ltd. develops, produces, and sells food and feed additives for pharmaceutical, nutritional, food, and animal feed industry.
Show moreShow less
It offers vitamins, such as biotin and folic acid; biological preservatives, including nisin, polylysine, and natamycin; and intermediate APIs. The company was incorporated in 1999 and is headquartered in Tiantai, China.
Stock analysis
Zhejiang Shengda Pharm (603079) currently trades at ¥11.33, while our model-based Fair Value estimate is ¥5.77, 49% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥7.56 per share, and 2 of the 16 models we run sit above the ¥11.33 price.
Bear case: the Asset-Based group reads lowest at ¥2.10, and 14 of the 16 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥4.25 (bear) to ¥5.98 (bull), the price of ¥11.33 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Zhejiang Shengda Pharm reported revenue of 845M CNY in FY2025 versus 790M CNY in FY2021, a compound +1.7%/yr. Reported net income was 62.2M CNY in FY2025, compounding −4.8%/yr from FY2021.
Key figures
Market cap 2.1B CNY (≈ $321M) Small · P/E ratio 47.2 · P/S ratio 2.57 · EPS (TTM) ¥0.2400 · Dividend yield 0.9% · Net margin 5.4% · Return on equity 3.3% · Return on assets (EBIT) 2.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (low confidence).
What moves the price
The share trades about 48% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −49%, 603079 screens richer than that median.
Fair Value models
Bear¥4.25Fair Value ¥5.77Bull¥5.98
Price ¥11.33 · Downside -49.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.1201 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.24/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+2.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.5%
Start year 2020 (pandemic). Over 10 years: +4.6% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
−23.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−24.8%
Dividend (yield on the price)0.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−5.7% vs −4.5%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.29% → 10%
2025 sits 88% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 1/13 measures
Overall it trails its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside−49.1% · Below median
Profitability
Return on equity (12 months)3.3% · Below median
Return on assets2.8% · Below median
Net margin (12 months)5.4% · Below median
Operating margin (12 months)7.8% · Below median
Growth and dividend
Revenue growth (quarter YoY)1.2% · Below median
Dividend yield (12 months)0.9% · Below median
Balance sheet
Debt / equity0.20× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)47.2× · Priciest 25%
P/B1.35× · Cheaper than median
P/S (12 months)2.57× · Pricier than median
EV/EBITDA14.7× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)6· sector 25
PAST (return on equity)13· sector 29
HEALTH (low debt)90· sector 96
DIVIDEND (yield)18· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Zhejiang Shengda Pharm (603079) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of ¥5.77 versus a price of ¥11.33, about 49% lower (overvalued).
What is the fair value of 603079?
Our model-based fair value for Zhejiang Shengda Pharm is ¥5.77 (as of Nov 7, 2026), built from audited fundamentals. The current price: ¥11.33.
What is the quality score of 603079?
Zhejiang Shengda Pharm has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zhejiang Shengda Pharm (603079)?
Our model-based price target is the fair value of ¥5.77 (as of Nov 7, 2026) from 16 valuation models. Cautious scenario ¥4.25, optimistic scenario ¥5.98. It is a calculation from audited fundamentals, not an analyst target.
What is the Zhejiang Shengda Pharm stock forecast for 2026?
Our models put fair value at ¥5.77, about 49% lower versus a price of ¥11.33 (overvalued). Cautious scenario ¥4.25, optimistic scenario ¥5.98. The calculation is refreshed regularly with new filings.
What is the revenue of Zhejiang Shengda Pharm (603079)?
Zhejiang Shengda Pharm reported trailing-twelve-month revenue of about 833M CNY (latest available figure, as of Nov 7, 2026).
Does Zhejiang Shengda Pharm pay a dividend?
Zhejiang Shengda Pharm currently shows a dividend yield of 0.88% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Zhejiang Shengda Pharm (603079) and when is the ex-dividend date?
Zhejiang Shengda Pharm pays a dividend of ¥0.1 per share a year, a dividend yield of 0.9%. The last ex-dividend date was Jul 1, 2026. The payout ratio is 41.7% of earnings. Our assessment: Token dividend. At a yield of 0.9% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.9% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Zhejiang Shengda Pharm (603079)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zhejiang Shengda Pharm it is ¥5.77 per share (as of Nov 7, 2026), against a price of ¥11.33. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Zhejiang Shengda Pharm stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 603079 trades above its calculated fair value: price ¥11.33, fair value ¥5.77, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 603079?
No. The price is what the market pays today (¥11.33); the fair value is what the company's own numbers justify (¥5.77). For Zhejiang Shengda Pharm the two are ¥5.56 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zhejiang Shengda Pharm worth?
The market values Zhejiang Shengda Pharm at about 2.1B CNY (market capitalisation, as of Nov 7, 2026). Per share that is ¥11.33; our models calculate a fair value of ¥5.77 per share.
What do the bullish and bearish scenarios say about 603079?
Our models span a range for Zhejiang Shengda Pharm: cautious scenario ¥4.25, base ¥5.77, optimistic ¥5.98 per share (as of Nov 7, 2026, price ¥11.33). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 603079?
Zhejiang Shengda Pharm trades at a price-to-earnings ratio of 47.2 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥5.77 is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2020 to 2025), reported earnings: 53.9. Other multiples: P/B 1.4, P/S 2.6, EV/EBITDA 14.7.
How solid is the balance sheet of Zhejiang Shengda Pharm (603079)?
Balance-sheet figures for Zhejiang Shengda Pharm (as of Nov 7, 2026): return on equity 3.3%, debt of 0.20 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 603079 from its 52-week high?
Zhejiang Shengda Pharm trades at ¥11.33, about 48% below its 52-week high of ¥21.99 and 13% above the low of ¥10.04 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥5.77 is for.
Which stocks are comparable to Zhejiang Shengda Pharm?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zhejiang Shengda Pharm stock attractive at the current price?
The data as of Nov 7, 2026: price ¥11.33, calculated fair value ¥5.77 (−49%), Quality Score 46/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 603079 calculated?
We run Zhejiang Shengda Pharm through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥5.77 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Zhejiang Shengda Pharm itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zhejiang Shengda Pharm (603079)?
The closing price on Nov 6, 2026 was ¥11.33. Our model-based fair value is ¥5.77, about 49% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zhejiang Shengda Pharm right now?
The price sits above even our optimistic bull case (¥5.98). The favourable scenario is already priced in. Weak quality (46/100) and above fair value at the same time, the margin of safety is missing on both counts.
Where does the earnings growth of Zhejiang Shengda Pharm (603079) come from?
Earnings per share at Zhejiang Shengda Pharm grew −11.7 % a year from 2013 to 2024. Broken into its drivers: revenue per share +1.9 %, EBIT margin −11.4 %, tax rate −0.8 %, residual (interest, one-offs) −1.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Zhejiang Shengda Pharm
How large is the market capitalisation of Zhejiang Shengda Pharm (603079)?
The market capitalisation of Zhejiang Shengda Pharm is 2.1B CNY (≈ $321M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zhejiang Shengda Pharm (603079)?
The price-to-sales ratio of Zhejiang Shengda Pharm is 2.57 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zhejiang Shengda Pharm (603079)?
Earnings per share at Zhejiang Shengda Pharm are ¥0.2400 (price ÷ EPS = P/E 47.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Zhejiang Shengda Pharm (603079)?
The dividend yield of Zhejiang Shengda Pharm is 0.9% (payout 41.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Zhejiang Shengda Pharm (603079)?
The net margin of Zhejiang Shengda Pharm is 5.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zhejiang Shengda Pharm (603079)?
The return on equity (ROE) of Zhejiang Shengda Pharm is 3.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zhejiang Shengda Pharm (603079)?
On an EBIT basis the return on assets of Zhejiang Shengda Pharm is 2.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zhejiang Shengda Pharm (603079)?
The operating margin of Zhejiang Shengda Pharm is 7.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zhejiang Shengda Pharm (603079)?
Revenue at Zhejiang Shengda Pharm is growing +1.2% versus a year earlier (3y avg +4.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zhejiang Shengda Pharm (603079)?
Earnings per share at Zhejiang Shengda Pharm are growing −56.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Zhejiang Shengda Pharm (603079) generate?
The free cash flow of Zhejiang Shengda Pharm is −6.8M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Zhejiang Shengda Pharm (603079) hold?
Zhejiang Shengda Pharm holds more cash than debt, 54.1M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Zhejiang Shengda Pharm in the live analysis
One click puts Zhejiang Shengda Pharm on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 7, 2026